Ординатура / Офтальмология / Английские материалы / Dry Eye and Ocular Surface Disorders_Pflugfelder, Beuerman, Elliot Stern_2004

13.Cavanagh HD, Colley AM. The molecular basis of neurotrophic keratitis. Acta Ophthalmol Suppl 1989; 192:115–134.

14.Liebman SD. Ocular manifiestations of Riley-Day syndrome. Arch Ophthalmol 1956; 56:719–725.

15.Kroop IG. The production of tears in familial dysautonomia: preliminary report. J Pediatr 1956; 48:328–329.

16.Smith AA, Dancis J, Breinin G. Ocular responses to autonomic drugs in familial dysautonomia. Invest Ophthalmol Vis Sci 19654:358–361.

17.Dunnington JH. Congenital alacrima in familial autonomic dysfunction. Arch Ophthalmol 1954; 52:925–931.

18.Pushker N, Dada T, Vajpayee RB, Gupta V, Aggrawal T, Titiyal JS. Neurotrophic keratopathy. CLAO J 2001; 27:100–107.

19.Zaal MJ, Volker-Dieben HJ, D’Amaro J. Risk and prognostic factors of postherpetic neuralgia and focal sensory denervation: a prospective evaluation in acute herpes zoster ophthalmicus. Clin J Pain 2000; 16:345–351.

20.Martin XY, Safran AB. Corneal hypoesthesia. Surv Ophthalmol 1988; 33:28–40.

21.Keijser S, van Best JA, Van der Lelij A, Jager MJ. Reflex and steady state tears in patients with latent stromal herpetic keratitis. Invest Ophthalmol Vis Sci 2002; 43:87–91.

22.Liesegang TJ. Physiologic changes of the cornea with contact lens wear. CLAO J 2002; 28:12–27.

23.Murphy PJ, Patel S, Marshall J. The effect of long-term, daily contact lens wear on corneal sensitivity. Cornea 2001; 20:264–269.

24.Sanaty M, Temel A. Corneal sensitivity changes in long-term wearing of hard polymethylmethacrylate contact lenses. Ophthalmologica 1998; 212:328–330.

25.Inoue K, Kato S, Ohara C, Numaga J, Amano S, Oshika T. Ocular and systemic factors relevant to diabetic keratoepitheliopathy. Cornea 2001; 20:798–801.

26.Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology 2001; 108:586–592.

27.Rosenberg ME, Tervo TM, Immonen IJ, Muller LJ, Gronhagen-Riska C, Vesaluoma MH. Corneal structure and sensitivity in type 1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000; 41:2915–2921.

28.Rosenberg ME, Tervo TM, Gallar J, Acosta MC, Muller LJ, Moilanen JA, Tarkkanen AH, Vesaluoma MH. Corneal morphology and sensitivity in lattice dystrophy type II (familial amyloidosis, Finnish type). Invest Ophthalmol Vis Sci 2001; 42:634–641.

29.Javaloy Estan J, Aracil Marco A, Belmonte Martinez J, Gallar J. Corneal trophism and sensitivity changes after penetrating keratoplasty. Arch Soc Esp Oftalmol 2000; 75:595–604.

30.Richter A, Slowik C, Somodi S, Vick HP, Guthoff R. Corneal reinnervation following penetrating keratoplasty—correlation of esthesiometry and confocal microscopy. Ger J Ophthalmol 1996; 5:513–517.

31.Matsui H, Kumano Y, Zushi I, Yamada T, Matsui T, Nishida T. Corneal sensation after correction of myopia by photorefractive keratectomy and laser in situ keratomileusis. J Cataract Refract Surg 2001; 27:370–373.

32.Perez-Santonja JJ, Sakla HF, Cardona C, Chipont E, Alio JL. Corneal sensitivity after photorefractive keratectomy and laser in situ keratomileusis for low myopia. Am J Ophthalmol 1999; 127:497–504.

33.Linna TU, Vesaluoma MH, Perez-Santonja JJ, Petroll WM, Alio JL, Tervo TM. Effect of myopic LASIK on corneal sensitivity and morphology of subbasal nerves. Invest Ophthalmol Vis Sci 2000; 41:393–397.

34.Seedor JA, Lamberts D, Bergmann RB, Perry HD. Filamentary keratitis associated with diphenhydramine hydrochloride (Benadryl). Am J Ophthalmol 1986; 101:376–377.

35.Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol 2000; 118:1264–1268.

36.Mader TH, Stulting RD. Keratoconjunctivitis sicca caused by diphenoxylate hydrochloride with atropine sulfate (Lomotil). Am J Ophthalmol 1991; 111:377–378.

37.Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci 2001; 42:321–327.

38.Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA. In vivo mapping of cholinergic terminals in normal aging, Alzheimer’s disease, and Parkinson’s disease. Ann Neurol 1996; 40:399–410.

39.Tremble GE, Penfield W. Operative exposure of the facial canal with removal of a tumor. Arch Otolaryngol 1936; 23:573–579.

40.May M, Harding WB Jr. Facial palsy: interpretation of neurologic findings. Trans Am Acad Ophthalmol Otolaryngol 1977; 84:710–722.

41.Deuschl G, Goddemeier C. Spontaneous and reflex activity of facial muscles in dystonia, Parkinson’s disease, and in normal subjects. J Neurol Neurosurg Psychiatry 1998; 64:320–324.

42.Obata H, Yamamoto S, Horiuchi H, Machinami R. Histopathologic study of human lacrimal gland. Ophthalmology 1995; 102:678–686.

43.Murray SB, Lee WR, Williamson J. Aging changes in the lacrimal gland. A histological study. Clin Exp Gerontol 19813:1–27.

44.Draper CE, Adeghate EA, Singh J, Pallot DJ. Evidence to suggest morphological and physiological alterations of lacrimal gland acini with ageing. Exp Eye Res 1999; 68:265–276.

45.Nasu M, Matsubara O, Yamamoto H. Post-mortem prevalence of lymphocytic infiltration of lacrymal gland: a comparative study in autoimmune and non-autoimmune diseases. J Pathol 1984; 143:11–15.

46.Mathers WD, Lane JA, Zimmerman MB. Tear film changes associated with normal aging. Cornea 1996; 15:229–234.

47.Nava A, Barton K, Monroy DC, Pflugfelder SC. The effects of age, gender and fluid dynamics on the concentration of tear film epidermal growth factor. Cornea 1997; 16:430–438.

48.Whittum-Hudson JA, Taylor HR, Farazdaghi M, Prendergast RA. Immunohistochemical study of the local inflammatory response to chlamydial ocular infection. Invest Ophthalmol Vis Sci 1986; 27:64.

49.Duke-Elder S. System of Ophthalmology. Vol 8, Pt 1, London: Klimpton, 1965.

50.Mondino BJ. Cicatricial pemphigoid and erythema multiforme. Ophthalmology 97:939, 1990.

51.Ralph RA. Conjunctival goblet cell density in normal subjects and dry eye syndromes. Invest Ophthalmol Vis Sci 1975; 14:299.

52.Fiore PM. Drug-induced ocular cicatrization. Int Ophthalmol Clin 1989; 29:147–150.

53.Huff JC, Weston WL, Tonnessen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8:763.

54.Howard GM. The Stevens-Johnson syndrome: ocular diagnosis and treatment. Am J Ophthalmol 1963; 55:893.

55.Foster CS, Fong LP, Azar D, Kenyon K. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology 1988; 95:453.

56.Lemp MA. Cornea and sclera. Arch Ophthalmol 1974; 92:158.

57.Sullivan DA, Wickham LA, Rocha EM, Kelleher RS, Silveira LA, Toda I. Influence of gender, sex steroid hormones and the hypothalamic-pituitary acis in the structure and function of the lacrimal gland. Adv Exp Med Biol 1998; 438:11–42.

58.Sullivan DA, Hann LE. Hormonal influence on the secretory immune function of the eye: endocrine impact on the lacrimal gland accumulation and secretion of IgA and IgG. J Steroid Biochem 1989; 34:253–262.

59.Sullivan DA, Sullivan BD, Ullman MD, Rocha EM, Krenzer KL, Cermak JM, Toda I, Doane MG, Evans JE, Wickham LA. Androgen influence on the meibomian gland. Invest Ophthalmol Vis Sci 2000; 41:3732–3742.

60.Murillo-Lopez F, Pflugfelder SC. Dry eye. In The Cornea. Krachmer J, Mannis M, Holland E, eds. St Louis: Mosby, 1996:663–686.

61.Schaumberg DA, Buring JE, Sullivan DA, Dana MR. Hormone replacement therapy and dry eye syndrome. JAMA 2001; 286:2114–2119.

62.Frankel S, Ellis P. Effect of oral contraceptives on tear production. Ann Ophthalmol 1978; 10:1585–1588.

63.Heath P. Ocular lymphomas. Am J Ophthalmol 1949; 32:1213–1223.

64.James DG. Ocular sarcoidosis. Br J Ophthalmol 1964; 48:461–470.

65.Drosos AA, Constantopoulos SH, Psychos D, Stefanou D, Papadimitriou CS, Moutsopoulos HM. The forgotten cause of sicca complex; sarcoidosis. J Rheumatol 1989; 16:1548–1551.

66.Fox RI. Systemic diseases associated with dry eye. Int Ophthalmol Clin 1994; 34:71–87.

67.Itescu S. Diffuse infiltrative lymphocytosis syndrome in human immunodeficiency virus infection: a Sjögren’s like disease. Rheum Dis Clin N Am 1991; 17:99–115.

68.Lucca JA, Farris RL, Bielory L, Caputo AR. Keratoconjunctivitis sicca in male patients infected with human immunodeficiency virus type I. Ophthalmology 1990; 97:1008–1010.

69.Abe T, Nakajima A, Matsunaga M, Sakuragi S, Komatsu M. Decreased tear lactoferrin concentration in patients with chronic hepatitis C. Br J Ophthalmol 1999; 83:684–687.

70.Siagris D, Pharmakakis N, Christofidou M, Petropoulos JK, Vantzou C, Lekkou A, Gogos CA, Labropoulou-Karatza C. Keratoconjunctivitis sicca and chronic HCV infection. Infection 2002; 30:229–233.

71.Pflugfelder SC, Roussel TJ, Culbertson WW. Primary Sjögren’s syndrome after infectious mononucleosis. JAMA 1987; 257:1049–1050.

72.Whittingham S, McNeilage J, Mackay IR. Primary Sjögren’s syndrome after infectious mononucleosis. Ann Intern Med 1987; 102:490–493.

73.Merayo-Lloves J, Baltatzis S, Foster CS. Epstein-Barr virus dacryoadenitis resulting in keratoconjunctivitis sicca in a child. Am J Ophthalmol 2001; 132:922–923.

74.Pflugfelder SC, Crouse CA, Monroy D, Yen M, Rowe M, Atherton S. Epstein-Barr virus and the lacrimal gland pathology of Sjögren’s syndrome. Am J Pathol 1993; 143:49–64.

75.Ogawa Y, Okamoto S, Wakui M, Watanabe R, Yamada M, Yoshino M, Ono M, Yang HY, Mashima Y, Oguchi Y, Ikeda Y, Tsubota K. Dry eye after haematopoietic stem cell transplantation. Br J Ophthalmol 1999; 83:1125–1130.

76.Lawley TJ, Peck GL, Moutsopoulos HM, Gratwohl AA, Deisseroth AB. Scleroderma, Sjögren-like syndrome, and chronic graft versus host disease. Ann Intern Med 1983; 87:707–709.

77.Hirst LW, Jabs DA, Tutschka PJ, Green WR, Santos GW. The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 1983 Apr;101:580–584.

78.Jabs DA, Hirst LW, Green WR, Tutschka PJ, Santos GW, Beschorner WE. The eye in bone marrow transplantation. II. Histopathology. Arch Ophthalmol 1983 Apr; 101:585–590.

79.Sjögren H, Bloch KJ. Keratoconjunctivitis sicca and the Sjögren’s syndrome. Surv Ophthalmol 1971; 16:145–159.

80.Sjögren HS. Zur kenntnis der keratoconjunctivitis sicca (Keratitis folliformis bei hypofunktion der tranendrusen). Acta Ophthalmol (Copenh) 1933; 11:1–151.

81.Manthorpe R, Frost-Larsen K, Isager H, Prause JU. Sjögren’s syndrome: a review with emphasis on immunological features. Allergy 1981; 36:139–153.

82.Daniels TE, Talal N. Diagnosis and differential diagnosis of Sjögren’s syndrome. In: Talal N, Moutsopoulos HM, Kassan S, eds. Sjögren’s Syndrome: Clinical and Immunological Aspects. Berlin: Springer-Verlag, 1987.

83.Fox RI, Robinson CA, Curd JG, Kozin F, Howell FV. Sjögren’s syndrome: proposed criteria for classification. Arthritis Rheum 1986; 29:577–585.

84.Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987; 66:648–653.

85.Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjögren’s Syndrome. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002 Jun; 61:554–558.

86.Pflugfelder SC, Tseng SCG, Sanabria O, Kell H, Garcia C, Felix C, Feuer W, Reis B. Evaluation of subjective assessments and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998; 17:38–56.

87.Tsubota K. The importance of the Schirmer test with nasal stimulation. Am J Ophthalmol 1991; 111:106.

88.Pflugfelder SC, Tseng SCG, Yoshino K, Monroy D, Felix C, Reis B. Correlation of goblet cell density and mucosal epithelial mucin expression with rose bengal staining in patients with ocular irritation. Ophthalmology 1997; 104:223–235.

89.Pepose JS, Akata RF, Pflugfelder SC, Voight W. Mononuclear cell phenotypes and immunoglobulin gene rearrangements in lacrimal gland biopsies from patients with Sjögren’s syndrome. Ophthalmology 1990; 97:1599–1605.

90.Pflugfelder SC. Lacrimal gland epithelial and immunopathology of Sjögren’s syndrome. In: Homma M, ed. Proceedings of the IV International Sjögren’s Syndrome Symposium, Amstelveen: Kugler, 1994.

91.Zhu Z, Stevenson D, Ritter T, Schechter JE, Mircheff AK, Kaslow HR, Trousdale MD. Expression of IL–10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea 2002; 21:210–214.

92.Zoukhri D, Hodges RR, Byon D, Kublin CL. Role of proinflammatory cytokines in the impaired lacrimation associated with autoimmune xerophthalmia. Invest Ophthalmol Vis Sci 2002; 43:1429–1436.

93.Kong L, Robinson CP, Peck AB, Vela-Roch N, Sakata KM, Dang H, Talal N, Humphreys-Beher MG. Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin Exp Rheumatol 1998; 16:675–681.

94.Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002; 13:5–16.

95.Kimura-Shimmyo A, Kashiwamura S, Ueda H, Ikeda T, Kanno S, Akira S, Nakanishi K, Mimura O, Okamura H. Cytokine-induced injury of the lacrimal and salivary glands. J Immunother 2002; 25(Suppl 1):S42–S51.

96.Bacman S, Berra A, Sterin-Borda L, Borda E. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome. Invest Ophthalmol Vis Sci 2001; 42:321–327.

97.Robinson CP, Brayer J, Yamachika S, Esch TR, Peck AB, Stewart CA, Peen E, Jonsson R, Humphreys-Beher MG. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren’s syndrome. Proc Natl Acad Sci USA 1998; 95:7538–7543.

98.Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci 2002; 43:1004–1011.

99.Danjo Y, Watanabe H, Tisdale AS, George M, Tsumura T, Abelson MB, Gipson IK. Alteration of mucin in human conjunctival epithelia in dry eye. Invest Ophthalmol Vis Sci 1998; 31:2602–2609.

100.Guzey M, Ozardali I, Basar E, Aslan G, Satici A, Karadede S. A survey of trachoma: the histopathology and the mechanism of progressive cicatrization of eyelid tissues. Ophthalmologica 2000; 214:277–284.

101.Wroblewska E. Squamous metaplasia of bulbar conjunctiva in the course of long-term topical antiglaucoma therapy. Klin Oczna 1999; 101:41–43.

102.Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM. Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant 1996; 18:641–642.

103.Nelson JD. Impression cytology. Cornea 1988; 7:71–81.

104.Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994; 112:1437–1445.

105.Ireland IA, Meyer DR. Ophthalmic manifestations of ectrodactyly-ectodermal dysplasia-clefting syndrome. Ophthal Plast Reconstr Surg 1998; 14:295–297.

106.Bonnar E, Logan P, Eustace P. Absent meibomian glands: a marker for EEC syndrome. Eye 1996; 10:355–361.

107.Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996; 40:343–367.

108.Hykin PG, Bron AJ. Age-related morphological changes in lid margin and meibomian gland anatomy. Cornea 1992; 11:334–342.

109.Henriquez AS, Korb DR. Meibomian glands and contact lens wear. Br J Ophthalmol 1981; 65:108–111.

110.Browning DJ, Proia AD. Ocular rosacea. Surv Ophthalmol 1986; 31:145–158.

111.Mathers WD, Shields WJ, Sachdev MS, Petroll WM, Jester JV. Meibomian gland morphology and tear osmolarity: changes with Accutane therapy. Cornea 1991; 10:286–290.

112.Sullivan DA, Sullivan BD, Evans JE, Schirra F, Yamagami H, Liu M, Richards SM, Suzuki T, Schaumberg DA, Sullivan RM, Dana MR. Androgen deficiency, Meibomian gland dysfunction, and evaporative dry eye. Ann N Y Acad Sci 2002; 966:211–222.

113.Fu YA. Ocular manifestation of polychlorinated biphenyls intoxication. Prog Clin Biol Res 1984; 137:127–132.

114.Tryphonas L, Truelove J, Zawidzka Z, Wong J, Mes J, Charbonneau S, Grant DL, Campbell JS. Polychlorinated biphenyl (PCB) toxicity in adult cynomolgus monkeys (M. fascicularis): a pilot study. Toxicol Pathol 1984; 12:10–25.

115.Farris RL. Tear osmolarity—a new gold standard? Adv Exp Med Biol 1994; 350:495–503.

116.Gilbard JP, Farris RL, Santamaria J 2nd. Osmolarity of tear microvolumes in keratoconjunctivitis sicca. Arch Ophthalmol 1978; 96:677–681.

117.Gilbard JP, Rossi SR. Tear film and ocular surface changes in a rabbit model of neurotrophic keratitis. Ophthalmology 1990; 97:308–312.

118.Gilbard JP, Rossi SR, Heyda KG. Tear film and ocular surface changes after closure of the meibomian gland orifices in the rabbit. Ophthalmology 1989; 96:1180–1186.

119.Gilbard JP, Gray KL, Rossi SR. A proposed mechanism for increased tear-film osmolarity in contact lens wearers. Am J Ophthalmol 1986; 102:505–507.

120.Gilbard JP, Farris RL. Ocular surface drying and tear film osmolarity in thyroid eye disease. Acta Ophthalmol (Copenh) 1983; 61:108–16.

121.Gilbard JP, Rossi SR, Gray KL. Mechanisms for increased tear film osmolarity. In: The Cornea: Transactions of the World Congress on the Cornea III. Cavanagh HD, ed. New York: Raven Press, 1988:5–7.

122.Gilbard JP, Rossi SR. Changes in tear ion concentrations in dry-eye disorders. Adv Exp Med Biol 1994; 350:529–533.

123.Gilbard JP, Rossi SR, Gray KL, Hanninen LA, Kenyon KR. Tear film osmolarity and ocular surface disease in two rabbit models for keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci 1988; 29:374–378.

124.Duzgun SA, Rasque H, Kito H, Azuma N, Li W, Basson MD, Gahtan V, Dudrick SJ, Sumpio BE. Mitogen-activated protein phosphorylation in endothelial cells exposed to hyperosmolar conditions. J Cell Biochem 2000; 76:567–571.

125.Bode JG, Gatsios P, Ludwig S, Rapp UR, Haussinger D, Heinrich PC, Graeve L. The mitogen-activated protein (MAP) kinase p38 and its upstream activator MAP kinase kinase 6 are involved in the activation of signal transducer and activator of transcription by hyperosmolarity. J Biol Chem 1999; 274:30222–30227.

126.Kyriakis JM, Avruch J. Protein kinase cascades activated by stress and inflammatory cytokines. Bioessays 1996; 18:567–577.

127.Nemeth ZH, Deitch EA, Szabo C, Hasko G. Hyperosmotic stress induces nuclear

factor-kappaB activation and interleukin-8 production in human intestinal epithelial cells. Am J Pathol 2002; 161:987–996.

129.Furuichi S, Hashimoto S, Gon Y, Matsumoto K, Horie T. p38 Mitogen-activated protein kinase and c-Jun-NH2-terminal kinase regulate interleukin-8 and RANTES production in hyperosmolarity stimulated human bronchial epithelial cells. Respirology 2002; 7:193–200.

130.Shin M, Yan C, Boyd D. An inhibitor of c-jun aminoterminal kinase (SP600125) represses c-Jun activation, DNA-binding and PMA-inducible 92-kDa type IV collagenase expression. Biochim Biophys Acta 2002; 1589:311–316.

131.Simon C, Simon M, Vucelic G, Hicks MJ, Plinkert PK, Koitschev A, Zenner HP. The p38 SAPK pathway regulates the expression of the MMP-9 collagenase via AP-1-dependent promoter activation. Exp Cell Res 2001; 271:344–355.

132.Mengshol JA, Vincenti MP, Brinckerhoff CE. IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 29:4361–4372.

133.Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 2001; 108:73–81.

134.Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, Karin M, Lin A. Inhibition of JNK activation through NF-kappaB target genes. Nature 2001; 414:313–317.

135.Kerby GS, Cottin V, Accurso FJ, Hoffmann F, Chan ED, Fadok VA, Riches DW. Impairment of macrophage survival by NaCl: implications for early pulmonary inflammation in cystic fibrosis. Am J Physiol Lung Cell Mol Physiol 2002; 283:L188–197.

136.Frasch SC, Nick JA, Fadok VA, Bratton DL, Worthen GS, Henson PM. p38 Mitogen-activated protein kinase-dependent and -independent intracellular signal transduction pathways leading to apoptosis in human neutrophils. J Biol Chem 1998; 273:8389–8397.

137.Zhao H, Jumblatt JE, Wood TO, Jumblatt MM. Quantification of MUC5AC protein in human tears. Cornea 2001; 20:873–877.

138.Argueso P, Balaram M, Spurr-Michaud S, Keutmann HT, Dana MR, Gipson IK. Decreased levels of the goblet cell mucin MUC5AC in tears of patients with Sjogren syndrome. Invest Ophthalmol Vis Sci 2002; 43:1004–1011.

139.Hicks SJ, Corfield AP, Kaswan RL, Hirsh S, Stern M, Bara J, Carrington SD. Biochemical analysis of ocular surface mucin abnormalities in dry eye: the canine model. Exp Eye Res 1998; 67:709–718.

140.Argueso P, Tisdale A, Mandel U, Letko E, Foster CS, Gipson IK. The cell-layer- and cell-type-specific distribution of GalNAc-transferases in the ocular surface epithelia is altered during keratinization. Invest Ophthalmol Vis Sci 2003; 44:86–92.

141.McCulley JP, Shine WE. The lipid layer: the outer surface of the ocular surface tear film. Biosci Rep 2001; 21:407–418.

142.Bron AJ, Tiffany JM. Shine WE, McCulley JP. The meibomian glands and tear film lipids. Structure, function, and control. Adv Exp Med Biol 1998; 438:281–295.

143.Shine WE, McCulley JP. Keratoconjunctivitis sicca associated with meibomian secretion polar lipid abnormality. Arch Ophthalmol 1998; 116:849–852.

144.Aho VV, Nevalainen TJ, Saari KM. Group IIA phospholipase A2 content of tears in patients with keratoconjunctivitis sicca. Graefes Arch Clin Exp Ophthalmol 2002; 240:521–523.

145.Nguyen DH, Beuerman RW, Meneray MA, Maitchouk D. Sensory denervation leads to deregulated protein synthesis in the lacrimal gland. Adv Exp Med Biol 1998; 438:55–62.

146.Henderson JW, Prough WA. Influence of age and sex of flow of tears. Arch Ophthalmol 1950; 43:224–231.

147.McGill JI, Liakos GM, Goulding N, Seal DV. Normal tear protein profiles and age-related changes. Br J Ophthalmol 1984 May; 68:316–320.

148.Solomon A, Dursun D, Liu Z, Xie Y, Macri A, Pflugfelder SC. Proand antiinflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci 2001; 42:2283–2292.

149.Lucca JA, Nunez JN, Farris RL. A comparison of diagnostic tests for keratoconjunctivitis sicca: lactoplate, Schirmer and tear osmolarity. CLAO J 1990; 16:109–112.

150.Nava A, Barton K, Monroy DC, Pflugfelder SC. The effects of age, gender, and fluid dynamics on the concentration of tear film epidermal growth factor. Cornea 1997; 16:430–438.

151.Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren’s syndrome keratoconjunctivitis sicca. Curr Eye Res 1999; 19:201–211.

152.Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjogren syndrome. Ophthalmology 1998; 105:2327–2329.

153.Virtanen T, Konttinen YT, Honkanen N, Harkonen M, Tervo T. Tear fluid plasmin activity of dry eye patients with Sjögren’s syndrome. Acta Ophthalmol Scand 1997; 75:137–141.

154.Afonso A, Sobrin L, Monroy DC, Selzer M, Lokeshwar B, Pflugfelder SC. Tear fluid gelatinase B activity correlates with IL-1α concentration and fluorescein tear clearance. Invest Ophthalmol Vis Sci 1999; 40:2506–2512.

155.Sobrin L, Liu Z, Monroy DC, Solomon A, Selzer MG, Lokeshwar BL, Pflugfelder SC. Regulation of MMP-9 activity in human tear fluid and corneal epithelial culture supernatant. Invest Ophthalmol Vis Sci 2000; 41:1703–1709.

156.Smith VA, Rishmawi H, Hussein H, Easty DL. Tear film MMP accumulation and corneal disease. Br J Ophthalmol 2001; 85:147–153.

157.Sack RA, Beaton A, Sathe S, Morris C, Wilcox M, Bogart B. Towards a closed eye model of the pre-ocular tear layer. Prog Retin Eye Res 2000; 19:649–668.

158.Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Ann Rev Cell Dev Biol 2001; 17:463–516.